Skip to content

BRILiANT mood study

Randomised pilot trial of Blood pressure Rapid Intensive Lowering And Normal Treatment for mood and cognition in persistent depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN64524251
Enrollment
66
Registered
2012-12-06
Start date
2012-02-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementias and Neurodegenerative Diseases and Depression Mental and Behavioural Disorders Depressive episode, unspecified

Interventions

Participants are randomised to receive either rapid or standard blood pressure lowering treatment.

Sponsors

Gateshead Health NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We will identify older adults (aged 50-80) with a history of Major Depressive Disorder (MDD) with persistent depressive symptoms who also have inadequately treated hypertension. Subjects will have a history of MDD with Hamilton depression rating scale (HAMD) at baseline = 15, be 50 to 80 years old and currently have a BP >140/90 mmHg (threshold recommended by NICE for treatment if 10 year cardiovascular risk > 20% or symptomatic vascular disease). 1. Aged 50-80 (to minimise risk of including people with dementia or pre-dementia) 2. DSM-IV defined MDD will be assessed using SCID by trained staff. Study subjects will have a history of MDD and have current clinically important depressive symptoms (HAMD>15); they will not therefore be in remission and so will have scope for significant improvement in the trial. We will recruit subjects stable on single antidepressant therapy after at least 2 months at a standard dose. As in other depression studies the HAMD will be used for defining the study population but not as an outcome measure. The primary outcome measure will be the Montgomery Asberg Depression Rating Scale. 3. All subjects will have hypertension, defined as having a BP>140/90mmHg recorded as the average of the second and third of three seated BP measurements taken in the left arm at 5 minute intervals. Patients with treated hypertension may enter the study if they are taking only one BP lowering drug and their BP is >140/90mmHg. 4. MMSE >23 5. Medically stable (including no change in medication in the last month) 6. Patient has provided written informed consent for participation in the study prior to any site specific procedures 7. Male or female participants

Exclusion criteria

Exclusion criteria: 1. Any other DSM-IV Axis I disorder other than an anxiety disorder unless the depressive episode is considered to be secondary to the anxiety disorder, confirmed using the Structured Clinical Interview for DSM (SCID) 2. Dependence or harmful use of alcohol or other drug in the past 12 months 3. Taking two or more antihypertensive drugs 4. Clinical evidence of dementia 5. History or evidence from neurological examination of clinical stroke 6. History of bipolar or psychotic disorder 7. Severe renal or hepatic impairment 8. Pregnancy or planning to become pregnant within next 12 months or breast feeding 9. Use of other investigational study drugs within 30 days prior to study entry (defined as date of randomisation into study) 10. Previous participation in this study 11. Presence of cardiac pacemaker or other contraindications to MRI

Design outcomes

Primary

MeasureTime frame
Depression score on the Montgomery-Asberg Depression Rating Scale (MDRS) measured at 12 weeks

Secondary

MeasureTime frame
No secondary outcome measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026